Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Gynecologic 1Breast 1

Conditions

Breast Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Vaginal Atrophy 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Sexual Dysfunction, Physiological 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Depression 1Carcinoma, Ovarian Epithelial 1Anxiety Disorders 1

Interventions

Paclitaxel 57Carboplatin 51Bevacizumab 41Taxes 28liposomal doxorubicin 21Gemcitabine 19Immunoglobulin G 17Disulfides 17pembrolizumab 15Topotecan 12rucaparib 10Cyclophosphamide 9Cisplatin 9Docetaxel 8olaparib 7Doxorubicin 7pazopanib 6mirvetuximab soravtansine 6cediranib 6Nivolumab 6Magnetic Resonance Spectroscopy 6Specimen Handling 5sargramostim 4niraparib 4Surgical Procedures, Operative 4Drug Therapy 4Cytoreduction Surgical Procedures 4Albumin-Bound Paclitaxel 4veliparib 3fludarabine phosphate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Fallopian Tube Neoplasms × Dehydroepiandrosterone × Clear all
NCT01376349 2019-02-07

Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

Alliance for Clinical Trials in Oncology

Phase 3 Completed
464 enrolled 8 charts
BreastGynecologicOther

Carcinoma, Ovarian Epithelial, Anxiety Disorders, Breast Neoplasms, Uterine Cervical Neoplasms, Depression, Fallopian Tube Neoplasms, Sexual Dysfunction, Physiological, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡